Deutsche Märkte geschlossen

Santen Pharmaceutical Co., Ltd. (SNPHF)

Other OTC - Other OTC Verzögerter Preis. Währung in USD
Zur Watchlist hinzufügen
7,70-0,43 (-5,31%)
Börsenschluss: 10:20AM EST

Santen Pharmaceutical Co., Ltd.

Grand Front Osaka Tower A
4-20 Ofuka-cho Kita-ku
Osaka 530-8552
Japan
81 6 7664 8621
https://www.santen.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter4.315

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Takeshi ItoPres, CEO & Representative DirectorN/AN/A1959
Mr. Kazuo KoshijiChief Financial Officer & Chief Risk OfficerN/AN/AN/A
Mr. Minori HaraChief Digital & Information OfficerN/AN/AN/A
Ms. Kaori ItagakiGen. Mang. of Investor Relations GroupN/AN/AN/A
Ms. Mika MasunariGen. Counsel & Chief Compliance OfficerN/AN/AN/A
Ms. Nobuko KatoChief Communications OfficerN/AN/AN/A
Mr. Satoshi SuzukiSr. Corp. Officer & Head of Corp. Devel. DivisionN/AN/AN/A
Mr. Shinichi TeramachiCorp. Officer, Head of Sales Department & Japan Sales and Marketing DivisionN/AN/AN/A
Mr. Ippei KuriharaCorp. Officer and Head of Marketing Department, Japan Bus., Japan Sales & Marketing DivisionN/AN/AN/A
Mr. Kenji MorishimaCorp. Officer & Head of China Product Devel. DepartmentN/AN/AN/A
Die Beträge haben den Stand und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products, including Verkazia, which is used for the treatment of vernal keratoconjunctivitis; STN1008903, which is used for dry eye treatment; Eybelis for the treatment of glaucoma and ocular hypertension; Alesion, an anti-allergy ophthalmic solution; Diquas for the treatment for dry eye syndrome; and glaucoma products, such as Tapros, Tapcom, PRESERFLO MicroShunt, and ROCK inhibitor products. The company also developing various pharmaceutical products to treat glaucoma, such as STN1014000, which is in clinical preparation; STN1012600, which is in Phase II clinical trial; STN1011101, STN1013001, and STN1013900, which are in Phase III clinical trial; STN1011402, which is in Phase III clinical trial to treat allergies; STN1010904, which is in Phase II clinical trial to treat fuchs endothelial corneal dystrophy; STN1010905, which is in Phase II clinical trial to treat meibomian gland dysfunction; and STN1013600, which is in Phase I clinical trial to treat presbyopia. In addition, it provides STN1012701, which is in Phase III clinical trial to treat myopia; STN1013800, which is in clinical preparation to treat ptosis; STN6000100, which is in clinical preparation to treat retinitis pigmentosa; STN1013400, which is in Phase I clinical trial to treat myopia; and STN1012700, which is in Phase I clinical trial to treat myopia. Further, it offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Corporate Governance

Santen Pharmaceutical Co., Ltd.s ISS Governance QualityScore, Stand 28. Januar 2023, lautet 1. Die grundlegenden Scores sind Audit: 1, Vorstand: 2, Shareholderrechte: 2, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.